← All indications
Menorrhagia
Excessive uterine bleeding during MENSTRUATION.
Drugs by status
Approved for this indication (6)
Phase 4 trials (10)
Phase 3 trials (8)
Phase 2 trials (2)
Organizations
Organization Involved with Phase 4 Indications (19)
- Merck
- Teva
- National Institutes of Health (NIH)
- University of Washington
- Ohio State University
- Oregon Health and Science University
- Sydney Centre for Reproductive Health Research
- Thomas Jefferson University
- Mayo Clinic
- University of Campinas
- Rush University
- Scott and White Healthcare
- AMAG Pharmaceuticals, Inc.
- Canadian Hemophilia Society
- Government of Canada
- Ferring
- Hologic, Inc.
- My Duc Phu Nhuan Hospital
- Government of Nova Scotia
Organization Involved with Phase 3 Indications (21)
- Abbott
- AbbVie
- Myovant Sciences GmbH
- ObsEva SA
- Uteron Pharma S.A.
- Xanodyne Pharmaceuticals
- Medicines360
- University of Pittsburgh
- Duke University
- University of Eastern Finland
- University of Oulu
- University of Saskatchewan
- University of Tampere
- Assiut University
- University of Turku
- University of North Carolina at Chapel Hill
- University of Sherbrooke
- Carnegie Mellon University
- CSSS Chicoutimi
- Government of Finland
- University of Helsinki
Organization Involved with Phase 2 Indications (6)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (8)